Literature DB >> 511361

A pharmacokinetic study of bacampicillin in patients with chronic maxillary sinusitis.

M Sorri, K Jokinen, E Peltomäki.   

Abstract

The penetration of ampicillin into sinus mucosa and secretion after oral bacampicillin was studied in 30 patients subjected to radical maxillary sinus surgery. Bacampicillin in a dose of 1200 mg was administered orally before the operation and the concentrations in serum, sinus mucosa and secretion were assayed. The mean serum concentration (+/- SEM) reached its maximum of 13.4 +/- 1.2 micrograms/ml in about one hour. The mean concentrations in the secretion and mucosa after two to five hours were 1.6 +/- 0.5 micrograms/ml and 1.6 +/- 0.4 micrograms/ml respectively. The clinical course of the patients was mostly uneventful. Adverse effects probably caused by the drug were found in two cases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 511361     DOI: 10.1007/bf01659776

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  2 in total

1.  Evaluation of a micromethod for determination of antibiotic concentrations in plasma.

Authors:  B Jalling; A S Malmborg; A Lindman; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1972-06       Impact factor: 2.953

2.  Bacampicillin in acute exacerbations of chronic bronchitis--a dose-range study.

Authors:  F P Maesen; H Beeuwkes; B I Davies; H J Buytendijk; P J Brombacher; J Wessman
Journal:  J Antimicrob Chemother       Date:  1976-09       Impact factor: 5.790

  2 in total
  3 in total

Review 1.  Pharmacokinetics of bacampicillin tablets in adults.

Authors:  W A Craig
Journal:  Bull N Y Acad Med       Date:  1983-06

Review 2.  Studies on aminopenicillin developments. Proceedings of a symposium. Concluding remarks.

Authors:  T Bergan
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 3.  The aminopenicillins: development and comparative properties.

Authors:  D S Reeves; D W Bullock
Journal:  Infection       Date:  1979       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.